ALA-105
Claudin‑18.2+ gastric, gastro‑oesophageal junction, and pancreatic cancers
PreclinicalActive
Key Facts
Indication
Claudin‑18.2+ gastric, gastro‑oesophageal junction, and pancreatic cancers
Phase
Preclinical
Status
Active
Company
About Arovella
Arovella builds off‑the‑shelf CAR‑iNKT cell therapies to deliver multi‑targeted cancer immunotherapy.
View full company profile